Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-Assisted CBCT vs CBCT for PTSD in Dyads
NCT06044675Phase 2Recruiting
- Sponsor
- Remedy Group
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Remedy Group. Started Nov 2024; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06044675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044675.